Lindbrook Capital, LLC Morphic Holding, Inc. Transaction History

Lindbrook Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 31, 2024	BUY	$26.12 - $34.07 $783 - $1,022	30 Added 32.61%	122 $4,000
Q4 2023 Jan 31, 2024	BUY	$19.95 - $31.0 $1,556 - $2,418	78 Added 557.14%	92 $2,000
Q3 2023 Oct 25, 2023	BUY	$21.33 - $59.42 $149 - $415	7 Added 100.0%	14 $0
Q2 2023 Jul 28, 2023	BUY	$34.33 - $62.11 $240 - $434	7 New	7 $0
Q4 2022 Jan 24, 2023	SELL	$24.14 - $30.37 $313 - $394	-13 Reduced 54.17%	11 $0
Q3 2022 Nov 10, 2022	BUY	$22.23 - $33.37 $288 - $433	13 Added 118.18%	24 $1,000
Q2 2022 Aug 01, 2022	BUY	$19.74 - $43.01 $217 - $473	11 New	11 $0

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.